The estimated Net Worth of Vikas Goyal is at least $434 Thousand dollars as of 5 March 2021. Mr. Goyal owns over 1,000 units of Morphic Inc stock worth over $56,990 and over the last 7 years he sold MORF stock worth over $0. In addition, he makes $377,024 as Independent Director at Morphic Inc.
Sign up
Mr. Goyal MORF stock SEC Form 4 insiders trading
Vikas has made over 4 trades of the Morphic Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of MORF stock worth $70,000 on 5 March 2021.
The largest trade he's ever made was buying 428,571 units of Morphic Inc stock on 6 November 2017 worth over $5,999,994. On average, Vikas trades about 95,544 units every 152 days since 2017. As of 5 March 2021 he still owns at least 1,000 units of Morphic Inc stock.
You can see the complete history of Mr. Goyal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vikas Goyal biography
Vikas Goyal serves as Independent Director of the Company. Vikas Goyal has served as a member of our board of directors since June 2016. Mr. Goyal is currently Senior Vice President, Business Development at Pandion Therapeutics. Prior to joining Pandion Therapeutics in August 2019, Mr. Goyal was a Principal at S.R. One, Limited since 2011, the corporate venture capital arm of GlaxoSmithKline plc, in Cambridge, Massachusetts, where he managed investments in innovative drug discovery and development companies. Prior to joining S.R. One, Limited, Mr. Goyal was a consultant in the pharmaceutical and medical products practice at McKinsey and Company, a co-founder of Extera Partners, where he advised public and private life sciences companies, and a business development manager at Infinity Pharmaceuticals, Inc. He received his B.A. in Neurobiology from Harvard University and his M.B.A. in Health Care Management from the Wharton School of the University of Pennsylvania.
What is the salary of Vikas Goyal?
As the Independent Director of Morphic Inc, the total compensation of Vikas Goyal at Morphic Inc is $377,024. There are 7 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
How old is Vikas Goyal?
Vikas Goyal is 41, he's been the Independent Director of Morphic Inc since 2016. There are 19 older and no younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
What's Vikas Goyal's mailing address?
Vikas's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.
Insiders trading at Morphic Inc
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
What does Morphic Inc do?
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
What does Morphic Inc's logo look like?
Complete history of Mr. Goyal stock trades at Spero Therapeutics Inc, Morphic Inc, and Pandion Therapeutics
Morphic Inc executives and stock owners
Morphic Inc executives and other stock owners filed with the SEC include:
-
Timothy Springer,
Founder, Independent Director -
Alexey Lugovskoy,
Chief Development Officer -
Dr. Praveen P. Tipirneni M.D.,
CEO, Pres & Director -
William DeVaul,
General Counsel, Secretary -
Praveen Tipirneni,
President, Chief Executive Officer, Director -
Dr. Marc Schegerin M.B.A., M.D.,
CFO & COO -
Bruce Rogers,
Chief Scientific Officer -
Vikas Goyal,
Independent Director -
Gustav Christensen,
Independent Chairman of the Board -
Joseph Slattery,
Independent Director -
Otello Stampacchia,
Independent Director -
Norbert Bischofberger,
Independent Director -
Amir Nashat,
Independent Director -
Dr. Timothy A. Springer Ph.D.,
Founder, Independent Director & Member of Scientific Advisory Board -
Nilesh Kumar,
Independent Director -
Peter Linde,
Chief Medical Officer -
Robert Farrell,
Senior Vice President - Finance, Chief Accounting Officer -
Marc Schegerin,
Chief Financial Officer, Chief Operating Officer -
Adrian S. Ray Ph.D.,
Sr. VP and Head of Biology & Translation -
Blaise Lippa,
Sr. VP of Molecular Discovery -
William D. DeVaul Esq.,
Gen. Counsel & Sec. -
Dr. Bruce N. Rogers,
Chief Scientific Officer -
Robert E. Farrell Jr., CPA, CPA,
Sr. VP of Fin./Operations & Chief Accounting Officer -
Susannah Gray,
-
Nisha Nanda,
-
Martin Edwards,
-
Holdings A/S Novo,
10% owner -
Plc Gsk,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Simon Peter Cooper,
CMO